Outsourcing of development and manufacturing activities is critically increasing among several pharmaceutical manufacturers. This enables the companies to focus on their core competencies. Furthermore, research and development activities consume a significant amount of labor and expenses for many pharmaceutical manufacturers, and the infrastructure cost for the same is also significantly high. Hence, the economic efficiency offered by outsourcing drug development activities boosts the demand for bioanalytical testing services.
Several blockbuster drugs from recent decades are losing their patent protection. This will drive investments from companies in new molecule development. However, many of the major chronic disease areas are already crowded, leaving minimal scope for making a mark. This phenomenon has also prompted a number of companies to begin research in niche areas such as rare diseases and palliative care.
In order to ensure rapid commercialization of their products in the increasingly competitive pharmaceuticals market, more and more pharma companies are diverting their R&D activities to CROs, therefore driving the market's growth. Additional drivers of this market include the growing complexity of single-molecule entities, the growing complexity of molecules, and so on. This requires pharmaceutical developers to keep abreast of the latest technologies and developments, which can be conveniently handled by opting for bioanalytical testing services.
Market Synopsis
Services for large molecules to meet demand during the forecast period
Based on the molecule types, the small molecule segment captures the largest share of the global bioanalytical testing services market. Small molecules occupy a significant share of the overall market for generic and branded drugs, and with the upcoming patent expiries of many of these entities, manufacturers will increasingly seek bioanalytical tests for further innovation in these drugs and further pipeline development.
Large molecule segments, on the other hand, are expected to grow rapidly during the forecast period. The growth of this segment is attributed to the large biologics and amino acid-based drug pipeline. Bioanalytical testing of large molecules also requires significant skills and technical expertise, which can be efficiently met by outsourcing to bioanalytical test service providers.
Bioavailability and bioequivalence tests to gather prominent market share
ADME testing, pharmacodynamics (PD) testing, pharmacokinetics (PK) testing, bioavailability testing, and bioequivalence testing are some of the key test types gathering the largest revenue share in the market for bioanalytical testing services. Among these, bioequivalence and bioavailability testing occupies the largest revenue share in the global market, as these services have the highest registration. Other pharmacodynamic and pharmacokinetic tests will also pick up significantly during the forecast period.
North America and Asia Pacific will be used to determine global market trends.
At present, North America is the most prominent regional market for bioanalytical testing services. The dominance of North America is attributed to the domicile of several large pharmaceutical manufacturers, the large product pipeline at the USFDA, and the rapid adoption of advanced analytical technologies in the region.
North America is also characterized by the growing interest of drug developers and manufacturers to reduce their research and manufacturing costs and focus on core competencies, which is driving their interest in CDMO services. On the other hand, Asia-Pacific will witness rapid growth in terms of the swift influx of research outsourcing in the region. In Asia Pacific, India and China are the most important CRO hubs. The availability of services at low costs and the presence of higher skills drive the swift growth of the Asia-Pacific market.
Periods of History and Forecast
2016 is a historic year.
2017: Base Year
2018-2026: Forecast Period
This research report presents the analysis of each considered segment for the period from 2016 to 2026, using 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The bioanalytical testing services market report provides a quantitative assessment of the industry in terms of current and forecasted market size while also presenting the market dynamics. This market is segmented based on molecule types, test types, and geography.
Type of Molecule (2016-2026; US$ Mn)
Small Molecule
Large Molecule
Large Molecule LC-MS Analysis
Immunoassays
Pharmacokinetic (PK) Examinations
Anti-drug Antibody Tests
Other immunoassay tests
Others
Type of test (2016-2026; US$ Mn)
ADME Testing
Pharmacodynamic (PD) Evaluation
Pharmacokinetic (PK) Evaluation
Bioavailability Testing
Bioequivalence Testing
Others
Geography Segment (2016-2026; millions of dollars)
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Russia
Rest of Europe
Asia-Pacific
India
China
Japan
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC Countries
South Africa
Rest of Middle East and Africa
This report also includes a company profiles section that gives insights into the company overview, product portfolio, financial information, and key developments of major market players. The major players profiled in this report include IQVIA, PAREXEL International, Tandem Labs Inc., Pharmaceutical Product Development, LLC, Covance Inc., Celerion Inc., Eurofins Scientific, Charles River Laboratories, Inc., PRA Health Sciences, Pharmaron, QPS Holdings, ICON PLC, Syneos Health, Laboratory Corporation of America, and SGS SA.
Key questions are answered in this report.
What shall be the size of the global market for bioanalytical testing services during the forecast period from 2018 to 2026?
Which are the key contributing factors that support the upward growth of this market?
Which are the key opportunities and pain points that the current and aspiring market players need to assess?
What are the major strategies that major market players have been observed to employ?
Which segments occupy prominent market positions, and why?
Frequently Asked Questions:
The market for Bioanalytical Testing Services Market is expected to reach USD$ XX in 2026.
The Bioanalytical Testing Services Market is expected to see significant CAGR growth over the coming years, at XX% .
The report is forecasted from 2018 -2026.
The base year of this report is 2017.
PAREXEL International, Tandem Labs Inc., Pharmaceutical Product Development, LLC, Covance Inc.. are some of the major players in the global market.
